Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 10/2015

Open Access 01-10-2015 | Genetics and Microenvironment (X Cathelineau, Section Editor)

What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

Authors: Martin Spahn, Silvan Boxler, Steven Joniau, Marco Moschini, Bertrand Tombal, R. Jeffrey Karnes

Published in: Current Urology Reports | Issue 10/2015

Login to get access

Abstract

Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Reprint of: cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2015;51:1201–2.CrossRef
2.
3.
Leinonen KA, Saramäki OR, Furusato B, et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:2333–44.PubMedCentralCrossRefPubMed
4.
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21:1451–60.CrossRefPubMed
5.
Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181:401–12.CrossRefPubMed
6.
McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer. 2008;99:1296–301.PubMedCentralCrossRefPubMed
7.
Burdelski C, Bujupi E, Tsourlakis MC, et al. Loss of SOX9 expression is associated with PSA recurrence in ERG-positive and PTEN deleted prostate cancers. PLoS ONE. 2015;10, e0128525.PubMedCentralCrossRefPubMed
8.
Steurer S, Mayer PS, Adam M, et al. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol. 2014;66:978–81.CrossRefPubMed
9.
Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012;25:471–9.CrossRefPubMed
10.
Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–9.CrossRefPubMed
11.
Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011;17:5878–88.CrossRefPubMed
12.
Dal Pra A, Lalonde E, Sykes J, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res. 2013;19:5202–9.CrossRefPubMed
13.
FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8:230.PubMedCentralCrossRefPubMed
14.
Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, et al. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci. 2013;14:21414–34.PubMedCentralCrossRefPubMed
15.
Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE. 2013;8, e65064.PubMedCentralCrossRefPubMed
16.
Spahn M, Kneitz S, Scholz C-JJ, Stenger N, Rüdiger T, Ströbel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010;127:394–403.PubMed
17.•
Kneitz B, Krebs M, Kalogirou C, et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 2014;74:2591–603. These analyzis are standing out for several reasons. First, the described single biomarker had a high prediction of cancer related death (AUC 90.3 %). Second, these results were confirmed by an external validation in an independent cohort. Third, the reported functional analysis demonstrated the biological function of this biomarker as a tumor suppressor regulating the JAK/STAT signaling pathway and sensitization to interferon-gamma treatment. Thus offering the chance for new treatment modalities in the future.
18.
19.
Kumar A, White TA, MacKenzie AP, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA. 2011;108:17087–92.PubMedCentralCrossRefPubMed
20.
Alshalalfa M, Crisan A, Vergara IA, et al. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int. 2014. doi:10.​1111/​bju.​13013.
21.
Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8, e66855.PubMedCentralCrossRefPubMed
22.
Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190:2047–53.PubMedCentralCrossRefPubMed
23.
Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 2014;17:64–9.PubMedCentralCrossRefPubMed
24.
Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33:944–51.CrossRefPubMed
25.
Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015;67:778–86.CrossRefPubMed
26.
Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:1038–46.PubMedCentralCrossRefPubMed
27.•
Cooperberg M, Davicioni E, Crisan, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015;67(2):326–33. This report is of importance because it demonstrated the added value of this test to a standard clinical classification system.
28.
Cullen J, Rosner IL, Brand TC, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68:123–31.CrossRefPubMed
29.
Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–8.CrossRefPubMed
30.
Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.PubMedCentralCrossRefPubMed
31.
Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31:1428–34.CrossRefPubMed
32.
Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:848–53.PubMedCentralCrossRefPubMed
33.
Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30:1025–31.CrossRefPubMed
34.
35.
36.
Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67:8504–10.CrossRefPubMed
37.•
Boutros PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47:736–45. This report is important because it demonstrated tumor heterogeneity in a homogeneous group of patients with localized intermediate risk PCa underlining the urgent need of a more tailored, individualized treatment in these patients.
38.•
Robinson D, Van Allen EM, Wu Y-MM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28. This report is important because it demonstrated tumor heterogeneity in a homogeneous group of patients with localized intermediate risk PCa underlining the urgent need of a more tailored, individualized treatment in these patients.
39.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.CrossRefPubMed
40.
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.CrossRefPubMed
41.
Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–6.CrossRefPubMed
42.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.CrossRefPubMed
43.
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.CrossRefPubMed
44.
Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760–8.CrossRefPubMed
45.
Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14:893–900.PubMedCentralCrossRefPubMed
46.
Fizazi K, Fizazi KS, Higano CS, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31:1740–7.CrossRefPubMed
47.
Araujo JC, Trudel GCC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–16.CrossRefPubMed
48.
Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16:417–25.CrossRefPubMed
49.
Michaelson MD, Oudard S, Ou Y-CC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014;32:76–82.CrossRefPubMed
50.•
Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, et al. European perspective for effective cancer drug development. Nat Rev Clin Oncol. 2014;11:492–8. This report is of importance because it described how new disease oriented screening platforms can optimize drug access, personalized medicine and healthcare delivery. Such platforms are currently under development for colorectal, lung, melanoma, brain and prostate cancer within the EORTC network.
Metadata
Title
What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
Authors
Martin Spahn
Silvan Boxler
Steven Joniau
Marco Moschini
Bertrand Tombal
R. Jeffrey Karnes
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Urology Reports / Issue 10/2015
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0545-3

Other articles of this Issue 10/2015

Current Urology Reports 10/2015 Go to the issue

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Surgery for Primary Proximal Hypospadias with Ventral Curvature >30°

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Laparoscopic Single-Site Surgery in Pediatric Urology: Where Do We Stand Today?

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials

Urothelial Cancer (A Sagalowsky, Section Editor)

Obesity, Physical Activity and Bladder Cancer

Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

Female Urethral Diverticulum: Current Diagnosis and Management

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Update on Multicystic Dysplastic Kidney